hydroxychloroquine has been researched along with Cross Infection in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants." | 3.01 | Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. ( Abella, BS; Amaravadi, RK; Babushok, DV; Biney, BT; Frank, I; Gill, S; Gimotty, PA; Hensley, SE; Huang, AC; Hyman, MC; Jolkovsky, EL; Maillard, I; Milone, MC; Nasta, SD; Uspal, JE; Vogl, DT; Walsh, JC; Wiletyo, EP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rubin, EJ | 1 |
| Baden, LR | 1 |
| Morrissey, S | 1 |
| Lee, SH | 1 |
| Son, H | 1 |
| Peck, KR | 1 |
| Rogado, J | 1 |
| Pangua, C | 1 |
| Serrano-Montero, G | 1 |
| Obispo, B | 1 |
| Marino, AM | 1 |
| Pérez-Pérez, M | 1 |
| López-Alfonso, A | 1 |
| Gullón, P | 1 |
| Lara, MÁ | 1 |
| Sakai, R | 1 |
| Honda, S | 1 |
| Tanaka, E | 1 |
| Majima, M | 1 |
| Konda, N | 1 |
| Takada, H | 1 |
| Harigai, M | 1 |
| Abella, BS | 1 |
| Jolkovsky, EL | 1 |
| Biney, BT | 1 |
| Uspal, JE | 1 |
| Hyman, MC | 1 |
| Frank, I | 1 |
| Hensley, SE | 1 |
| Gill, S | 1 |
| Vogl, DT | 1 |
| Maillard, I | 1 |
| Babushok, DV | 1 |
| Huang, AC | 1 |
| Nasta, SD | 1 |
| Walsh, JC | 1 |
| Wiletyo, EP | 1 |
| Gimotty, PA | 1 |
| Milone, MC | 1 |
| Amaravadi, RK | 1 |
| Kumar, G | 1 |
| Adams, A | 1 |
| Hererra, M | 1 |
| Rojas, ER | 1 |
| Singh, V | 1 |
| Sakhuja, A | 1 |
| Meersman, M | 1 |
| Dalton, D | 1 |
| Kethireddy, S | 1 |
| Nanchal, R | 1 |
| Guddati, AK | 1 |
| Ahmed, W | 1 |
| Al Obaidli, AAK | 1 |
| Joseph, P | 1 |
| Smith, ER | 1 |
| Khan, AA | 1 |
| Anwar, S | 1 |
| Chandrasekar, T | 1 |
| Al Madani, AK | 1 |
| Dastoor, HD | 1 |
| Zahid, I | 1 |
| Costales, FA | 1 |
| Boobes, YAR | 1 |
| Al Kindi, F | 1 |
| Issa, SEK | 1 |
| Hassan, MH | 1 |
| George, A | 1 |
| Holt, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)[NCT04329923] | Phase 2 | 173 participants (Actual) | Interventional | 2020-04-09 | Terminated (stopped due to Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months (NCT04329923)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 3 HCQ | 4 |
| Cohort 3 Placebo | 4 |
Cohort 1 rate of hospitalization (NCT04329923)
Timeframe: until quarantine release
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 HCQ | 1 |
| Cohort 1 Placebo | 0 |
Cohort 1 rate of participant-reported secondary infection of housemates (NCT04329923)
Timeframe: until quarantine release, or approximately <20 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 HCQ | 2 |
| Cohort 1 Placebo | 2 |
Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital discharge (NCT04329923)
Timeframe: until hospital discharge
| Intervention | days (Median) |
|---|---|
| Cohort 2 HCQ High Dose | 5.5 |
| Cohort 2 HCQ Low Dose | 4 |
Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset. (NCT04329923)
Timeframe: until quarantine release or hospitalization
| Intervention | days (Median) |
|---|---|
| Cohort 1 HCQ | 8 |
| Cohort 1 Placebo | 11 |
1 trial available for hydroxychloroquine and Cross Infection
| Article | Year |
|---|---|
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Cross Infection; Double-Blind Method; Female; Hospitals, U | 2021 |
6 other studies available for hydroxychloroquine and Cross Infection
| Article | Year |
|---|---|
Audio Interview: New Research on Possible Treatments for Covid-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; | 2020 |
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Cross Infection; Disease Outbreaks; Hospitals; Hu | 2020 |
Covid-19 and lung cancer: A greater fatality rate?
Topics: Aged; Aged, 80 and over; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Cross Infe | 2020 |
The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Cross Infection; Databases, Factual; Female; Humans; Hydroxychloroquine | 2020 |
Predictors and outcomes of healthcare-associated infections in COVID-19 patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Coinfection; COVID-19; COVID-19 Drug Treatment; Cross Infec | 2021 |
Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Viral; Antiviral Agents; Asymptomatic Infections; Commun | 2021 |